Skip to main content
China NT Pharma Group Company Limited logo

China NT Pharma Group Company Limited — Investor Relations & Filings

Ticker · 1011 ISIN · KYG2114L1133 HKEX Manufacturing
Open in API
Filings indexed 717 across all filing types
Latest filing 2026-05-29 M&A Activity
Country HK Hong Kong
Listing HKEX 1011

About China NT Pharma Group Company Limited

http://www.ntpharma.com

China NT Pharma Group Company Limited is a pharmaceutical enterprise engaged in the research and development (R&D) of biotechnology, the manufacturing and sale of private-label and generic pharmaceuticals, and the provision of comprehensive pharmaceutical marketing and promotion services. The company acts as an agent for clients, selling medical and health-related products to external customers. Historically, the Group was a dominant force in the vaccine market, operating as China's largest comprehensive vaccine supply chain and promotion service provider. It distributed over 19 types of Class II vaccines, covering a significant portion of the national immunization infrastructure, and maintained long-term partnerships with major multinational pharmaceutical corporations such as GSK, Pfizer, and Novartis. The Group also manages investment and digital services businesses.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT IN RELATION TO THE PROPOSED DISPOSAL OF THE EQUITY INTERESTS IN NT PHARMA (OVERSEAS) HOLDING CO., LTD
M&A Activity Classification · 75% confidence The document is a voluntary announcement by China NT Pharma Group regarding its intention to dispose of equity interests in a subsidiary (NT Pharma (Overseas) Holding Co., Ltd). It describes preliminary directional discussions for a potential transaction, with no binding terms yet. This is a corporate transaction announcement (disposal of equity), fitting the M&A Activity category rather than financial results, governance changes, or routine regulatory filings. Therefore, the correct classification is M&A Activity (TAR).
2026-05-29 English
SUPPLEMENTAL ANNOUNCEMENT RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR
Board/Management Information Classification · 90% confidence The announcement is a supplemental disclosure regarding the resignation of an independent non-executive director and details disagreements with the Board. It clearly relates to a change in the company’s board of directors. This falls squarely under Board/Management Information (MANG).
2026-05-20 English
SUPPLEMENTAL ANNOUNCEMENT DISCLOSURE OF JUDICIAL PROCEDURE RECORDS OF A DIRECTOR
Legal Proceedings Report Classification · 95% confidence The document is a stock exchange announcement titled “Supplemental Announcement: Disclosure of Judicial Procedure Records of a Director”. It provides details of a consumption restriction order, related court proceedings, and bankruptcy reorganization of a former subsidiary arising from a loan dispute. There is no financial statement data or report attached; instead it is clearly an update on legal proceedings affecting the Group and a director. This matches the definition of Legal Proceedings Report (LTR).
2026-05-15 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Governance Information Classification · 81% confidence The document provides a static list of all directors and their committee memberships, detailing board composition and governance structure, without announcing any new appointments or changes. It outlines the board’s internal governance (committees and roles), which aligns with Governance Information (CGR) rather than a change notice (MANG).
2026-05-12 English
PAST NOTIFIABLE TRANSACTIONS AND CONNECTED TRANSACTIONS IN RELATION TO THE PROVISION OF FINANCIAL ASSISTANCE AND LOAN AGREEMENTS AND DISCLOSURE OF JUDICIAL PROCEDURE RECORDS OF A DIRECTOR
Regulatory Filings Classification · 85% confidence The document is an announcement made under the Hong Kong Listing Rules (Chapters 14 and 14A) regarding past notifiable and connected transactions, loan agreements and financial assistance. It provides disclosures, background, remedial actions and compliance information, but does not itself constitute a financial report (e.g., interim or annual report), proxy materials, dividend notice, or a detailed investor presentation. It is a generic regulatory disclosure of related‐party transactions and Listing Rules compliance, matching the fallback category of Regulatory Filings (RNS).
2026-05-11 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
Regulatory Filings Classification · 85% confidence The document is a routine monthly return (Form FF301) submitted to the Hong Kong Stock Exchange under Listing Rules Chapter 19B. It details movements in authorised and issued share capital, public float confirmations, and compliance confirmations rather than announcing a new share issue or reporting financial performance. It does not contain substantive financial statements or results (ruling out IR, 10-K, ER, etc.), nor is it a one-off capital change announcement (SHA) or officer certification (would default to RNS). Therefore it is best classified as a general regulatory filing (RNS).
2026-05-11 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.